https://scholars.lib.ntu.edu.tw/handle/123456789/630356
標題: | Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin | 作者: | CHEN-HUA LIU Liang, Cheng-Chao CHUN-JEN LIU TAI-CHUNG TSENG Lin, Chih-Lin Yang, Sheng-Shun TUNG-HUNG SU JOU-WEI LIN Chen, Jun-Herng PEI-JER CHEN DING-SHINN CHEN JIA-HORNG KAO |
關鍵字: | CHRONIC HEPATITIS-C; PEGINTERFERON ALPHA-2B; VIROLOGICAL RESPONSE; COMBINATION THERAPY; IL28B; TELAPREVIR; BOCEPREVIR; DIAGNOSIS; FIBROSIS | 公開日期: | 2012 | 出版社: | INT MEDICAL PRESS LTD | 卷: | 17 | 期: | 6 | 起(迄)頁: | 1059 | 來源出版物: | Antiviral therapy | 摘要: | Pegylated interferon and ribavirin for 72 weeks improve sustained virological response (SVR) in HCV genotype 1 (HCV-1) slow viral responders. Whether interleukin 28B (IL28B) single nucleotide polymorphism (SNP) genotypes and on-treatment viral responses can identify non-rapid virological response (RVR) patients who benefit from 48 or 72 weeks of therapy remains unclear. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/630356 | ISSN: | 1359-6535 | DOI: | 10.3851/IMP2322 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。